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Abridged abstract
Background The non-opioid, lidocaine, was investigated in 
several studies for its use in multimodal management strate-
gies to reduce postoperative pain and enhance recovery. This 
review was published in 2015 and updated in January 2017.
Objectives To assess the effects (benefits and risks) of peri-
operative intravenous (IV) lidocaine infusion compared to 
placebo/no treatment or compared to epidural analgesia on 
postoperative pain and recovery in adults undergoing various 
surgical procedures.
Selection criteria We included randomized controlled tri-
als comparing the effect of continuous perioperative IV 
lidocaine infusion either with placebo, or no treatment, or 
with thoracic epidural analgesia (TEA) in adults undergoing 
elective or urgent surgery under general anaesthesia. The 
IV lidocaine infusion must have been started intraopera-
tively, prior to incision, and continued at least until the end 
of surgery.
Data collection and analysis Our primary outcomes were 
pain score at rest, gastrointestinal recovery and adverse 
events. Secondary outcomes included postoperative nausea 
and postoperative opioid consumption.
Main results We included 23 new trials in the update. In 
total, the review included 68 trials (4525 randomized partici-
pants). Trials involved participants undergoing open abdom-
inal (22), laparoscopic abdominal (20), or various other sur-
gical procedures (26). The application scheme of systemic 
lidocaine strongly varies between the studies related to both 
dose (1–5 mg/kg/h) and termination of the infusion (from 
the end of surgery until several days after).
IV lidocaine compared to placebo We are uncertain whether 
IV lidocaine improves postoperative pain compared to pla-
cebo or no treatment at early time points (1–4 h) [standard-
ized mean difference (SMD) − 0.50, 95% confidence interval 
(CI) − 0.72 to − 0.28; 29 studies, 1656 participants; very 
low quality evidence) after surgery. Due to variation in the 
standard deviation (SD) in the studies, this would equate to 
an average pain reduction of between 0.37 and 2.48 cm on 
a 0–10-cm visual analogue scale. Assuming approximately 
1 cm on a 0–10-cm pain scale is clinically meaningful, we 
ruled out a clinically relevant reduction in pain with lido-
caine at intermediate (24 h) (SMD − 0.14, 95% CI − 0.25 
to − 0.04; 33 studies, 1847 participants; moderate-quality 
evidence), and at late time points (48 h) (SMD − 0.11, 95% 
CI − 0.25 to 0.04; 24 studies, 1404 participants; moderate-
quality evidence). Due to variation in the SD in the studies, 
this would equate to an average pain reduction of between 
0.10 and 0.48 cm at 24 h and 0.08 and 0.42 cm at 48 h. In 
contrast to the original review in 2015, we did not find any 
significant subgroup differences for different surgical proce-
dures. We are uncertain whether lidocaine reduces the risk of 
ileus [risk ratio (RR) 0.37, 95% CI 0.15–0.87; four studies, 
273 participants], time to first defaecation/bowel movement 
[mean difference (MD) − 7.92 h, 95% CI − 12.71 to − 3.13; 
12 studies, 684 participants], risk of postoperative nausea 
(overall, i.e. 0 up to 72 h) (RR 0.78, 95% CI 0.67–0.91; 35 
studies, 1903 participants), and opioid consumption (overall) 
(MD − 4.52 mg morphine equivalents, 95% CI − 6.25 to 
− 2.79; 40 studies, 2201 participants); quality of evidence 
was very low for all these outcomes.
IV lidocaine compared to TEA The effects of IV lidocaine 
compared with TEA are unclear [pain at 24 h (MD 1.51, 
95% CI − 0.29 to 3.32; two studies, 102 participants), pain 
at 48 h (MD 0.98, 95% CI − 1.19 to 3.16; two studies, 102 
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participants), time to first bowel movement (MD − 1.66, 
95% CI − 10.88 to 7.56; two studies, 102 participants); all 
very low quality evidence]. The risk for ileus and for post-
operative nausea (overall) is also unclear, as only one small 
trial assessed these outcomes (very low quality evidence). 
No trial assessed the outcomes, ‘pain at early time points’ 
and ‘opioid consumption (overall)’. The effect of IV lido-
caine on adverse effects compared to TEA is uncertain (very 
low quality evidence).
Authors’ conclusions We are uncertain whether IV perio-
perative lidocaine, when compared to placebo or no treat-
ment, has a beneficial impacton pain scores in the early 
postoperative phase, and on gastrointestinal recovery, post-
operative nausea, and opioid consumption. There is a lack 
of evidence about the effects of IV lidocaine compared with 
epidural anaesthesia in terms ofthe optimal dose and timing 
(including the duration) of the administration. We identified 
three ongoing studies, and 18 studies are awaiting classifica-
tion; the results of the review may change when these studies 
are published and included in the review.
Commentary
The concept of using intravenous lidocaine as an adjunct to 
general anaesthesia is appealing to the colorectal surgeon. 
The 2015 edition of this Cochrane review concluded that 
intravenous (IV) lidocaine had a positive impact on pain, 
gastrointestinal (GI) recovery, length of hospital stay and 
opioid requirements—impressive benefits for a cheap and 
easy intervention [1]. However, despite attracting interest, it 
has never gained widespread uptake. A revised analysis has 
just been published, adding 23 studies to give a total of 68 
trials with 4525 randomized participants [2]. At a glance, the 
updated abstract suggests that author conclusions have been 
substantially downgraded, and a busy colorectal surgeon 
could not be blamed for moving on. However, in addition 
to new data, the revision includes new analysis techniques, 
which, while methodologically sound, have not necessarily 
improved ease of understanding of the article. As ever, the 
devil is in the detail.
The main caveat is the tremendous heterogeneity of stud-
ies included for analysis. There is heterogeneity of opera-
tions (laparoscopic and open, abdominal and non-abdom-
inal), of physiological severity (ranging from breast and 
appendix surgery to open colectomy and prostatectomy), of 
dose and duration of IV lidocaine infusion (procedure only 
to over 24 h) and of geographical location/healthcare setting. 
Furthermore, if ever there was an illustration of what the 
late Doug Altman was getting at, it is here: small studies, 
moderate-to-poor methodology and inconsistent reporting 
of results [3]. You could be forgiven for raising an eyebrow 
as all of these data are emptied into the meta-analysis black 
box, and this is a key point in the technical analysis. Quite 
appropriately, the authors have accounted for study heteroge-
neity by reporting prediction interval, which in general finds 
that the dispersion of the true mean effects in the population 
is far greater than estimated by basic random effects meta-
analysis [4]. Hence, although the random effects confidence 
intervals in this review are suggestive of a beneficial effect 
of IV lidocaine on various outcomes including early pain 
scores (SMD − 0.50, 95% CI − 0.72 to − 0.28), postopera-
tive ileus (RR 0.37, 95% CI 0.15–0.87) and time to defeca-
tion (SMD − 7.92 h, 95% CI − 12.71 to − 3.13), conclusions 
are deemed uncertain because “the range of effects that can 
be expected in future studies (taking existing heterogeneity 
into account) indicated that lidocaine may not always be 
beneficial in an individual setting”. This is self-evident: a 
trial of the analgesic effects of oral paracetamol would be 
appropriate in the setting of simple headache but not in trau-
matic femoral shaft fracture. Despite the authors’ caveats, 
this review provides evidence that IV lidocaine may well 
have beneficial effects on recovery variables that are of sharp 
interest to the colorectal surgeon, but perhaps of less inter-
est to breast or spine surgeons. Our own meta-analysis of 
the existing studies conducted in the setting of colorectal 
surgery (four open and five laparoscopic) published in this 
issue supports this contention [5].
Perioperative IV lidocaine infusion is inexpensive, easy 
to administer and offers the possibility of clinical benefits 
of particular relevance to colorectal surgery. However, 
there remains a need for adequately powered and carefully 
designed studies within optimized perioperative care path-
ways to quantify that benefit (or definitively refute the out-
comes obtained from small, biased, poorly designed studies). 
To fulfil this objective, two methodological points should be 
incorporated. First, return of GI function is a key recovery 
outcome for colorectal surgery that is inadequately described 
by univariate measures (such as time to first flatus, time to 
first bowel movement, and episodes of vomiting). Existing 
composite endpoints (GI-2 and GI-3) of return of gut func-
tion have been validated and should be reported [6]. Second, 
although we know the important elements of optimal perio-
perative care, researchers need to report compliance with 
these elements to interpret the effect of interventions. For 
example, average length of stay in the existing trials of IV 
lidocaine in laparoscopic colorectal surgery ranged from 3 to 
8 days, suggesting considerable differences in perioperative 
management. Furthermore, the biggest effect size was found 
in those studies reporting high compliance with enhanced 
recovery principles and short length of stay. It may be that a 
benefit was not detected in other studies because it was lost 
in the ‘noise’ of a suboptimal patient pathway.
In summary, this Cochrane review suggests that periop-
erative IV lidocaine could be very beneficial to colorectal 
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surgery patients. We need to up our game in conducting 
robust studies to test it within best practice settings.
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